Skip to menu Skip to content Skip to footer
Professor

Steve Deitelzweig

Email: 

Overview

Availability

Professor Steve Deitelzweig is:
Available for supervision

Works

Search Professor Steve Deitelzweig’s works on UQ eSpace

103 works between 1994 and 2023

41 - 60 of 103 works

2016

Journal Article

Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin

Margolis, Jay M., Deitelzweig, Steven, Kline, Jeffrey, Tran, Oth, Smith, David M., Crivera, Concetta, Bookhart, Brahim and Schein, Jeff (2016). Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin. Clinical Therapeutics, 38 (11), 2496-2503. doi: 10.1016/j.clinthera.2016.09.007

Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin

2016

Journal Article

Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions

Margolis, Jay M., Deitelzweig, Steven, Kline, Jeffrey, Tran, Oth, Smith, David M., Bookhart, Brahim, Crivera, Concetta and Schein, Jeff (2016). Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. Journal of the American Heart Association, 5 (10) e003788. doi: 10.1161/JAHA.116.003788

Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions

2016

Journal Article

Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting

Deitelzweig, Steven, Laliberte, Francois, Crivera, Concetta, Germain, Guillaume, Bookhart, Brahim K., Olson, William H., Schein, Jeffrey and Lefebvre, Patrick (2016). Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting. Clinical Therapeutics, 38 (8), 1803-1816. doi: 10.1016/j.clinthera.2016.07.002

Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting

2016

Journal Article

Multidrug-resistant gram-negative bacterial infections in the hospital setting: Overview, implications for clinical practice, and emerging treatment options

Cerceo, Elizabeth, Deitelzweig, Steven B., Sherman, Bradley M. and Amin, Alpesh N. (2016). Multidrug-resistant gram-negative bacterial infections in the hospital setting: Overview, implications for clinical practice, and emerging treatment options. Microbial Drug Resistance, 22 (5), 412-431. doi: 10.1089/mdr.2015.0220

Multidrug-resistant gram-negative bacterial infections in the hospital setting: Overview, implications for clinical practice, and emerging treatment options

2016

Journal Article

Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation

Deitelzweig, Steve, Evans, Michael, Hillson, Eric, Trocio, Jeffrey, Bruno, Amanda, Tan, Wilson, Lingohr-Smith, Melissa, Singh, Prianka and Lin, Jay (2016). Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion, 32 (1), 87-94. doi: 10.1185/03007995.2015.1103217

Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation

2016

Conference Publication

Compare major bleeding risk and associated costs among Nvaf patients with Cha2Ds2-vasc score >= 3 newly anticoagulated with apixaban versus warfarin

Deitelzweig, Steven, Gupta, Kiran, Ogbonnaya, Augustina, Shah, Manan, Farrelly, Eileen, Lokhandwala, Tasneem, Eaddy, Michael and Squibb, Bristol-Myers (2016). Compare major bleeding risk and associated costs among Nvaf patients with Cha2Ds2-vasc score >= 3 newly anticoagulated with apixaban versus warfarin. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)30877-4

Compare major bleeding risk and associated costs among Nvaf patients with Cha2Ds2-vasc score >= 3 newly anticoagulated with apixaban versus warfarin

2016

Conference Publication

Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban

Deitelzweig, Steven, Gupta, Kiran, Nadkarni, Anagha, Trocio, Jeffrey, Lin, Jay and Lingohr-Smith, Melissa (2016). Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)30806-3

Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban

2016

Conference Publication

Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors

Deitelzweig, S., Neuman, R., Lingohr-Smith, M. and Lin, J. (2016). Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. Congress of the European-Society-of-Cardiology (ESC), Rome Italy, Aug 27-31, 2016. OXFORD: OXFORD UNIV PRESS.

Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors

2016

Conference Publication

Hospital Length Of Stay And Hospitalization Costs For Pulmonary Embolism Comparing Patients Receiving Rivaroxaban Or Warfarin

Kline, J. A., Deitelzweig, S., Margolis, J. M., Raut, M., Tran, O., Smith, D. M., Crivera, C., Bookhart, B., Schein, J. and Olson, W. (2016). Hospital Length Of Stay And Hospitalization Costs For Pulmonary Embolism Comparing Patients Receiving Rivaroxaban Or Warfarin. International Conference of the American-Thoracic-Society (ATS), San Francisco, United States, May 13-18, 2016. NEW YORK: AMER THORACIC SOC.

Hospital Length Of Stay And Hospitalization Costs For Pulmonary Embolism Comparing Patients Receiving Rivaroxaban Or Warfarin

2016

Conference Publication

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants

Deitelzweig, Steve, Bruno, Amanda, Trocio, Jeffrey, Tate, Natalie, Gupta, Kiran, Lin, Jay and Lingohr-Smith, Melissa (2016). An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Abingdon, Oxfordshire, United Kingdom: Taylor & Francis. doi: 10.1185/03007995.2015.1131676

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants

2016

Conference Publication

Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stay

Deitelzweig, Steven, Kline, Jeffrey, Margolis, Jay M., Raut, Monika, Tran, Oth, Smith, David, Crivera, Concetta, Bookhart, Brahim, Schein, Jeff and Olson, William (2016). Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stay. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)32066-6

Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stay

2016

Conference Publication

Health Care Costs Among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban Versus Low-Molecular-Weight Heparin and Warfarin

Deitelzweig, S., Laliberte, F., Raut, R., Germain, G., Bookhart, B. K., Olson, W. H., Schein, J. and Lefebvre, P. (2016). Health Care Costs Among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban Versus Low-Molecular-Weight Heparin and Warfarin. ISPOR 21st Annual International Meeting, Washington, DC United States, 21 – 25 May 2016. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2016.03.102

Health Care Costs Among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban Versus Low-Molecular-Weight Heparin and Warfarin

2015

Journal Article

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure

McHorney, Colleen A., Crivera, Concetta, Laliberte, Francois, Nelson, Winnie W., Germain, Guillaume, Bookhart, Brahim, Martin, Silas, Schein, Jeffrey, Lefebvre, Patrick and Deitelzweig, Steven (2015). Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Current Medical Research and Opinion, 31 (12), 2167-2173. doi: 10.1185/03007995.2015.1096242

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure

2015

Journal Article

A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: Balancing the risks and benefits

Amin, Alpesh and Deitelzweig, Steven (2015). A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: Balancing the risks and benefits. Thrombosis Journal, 13 (29) 29, 29. doi: 10.1186/s12959-015-0056-y

A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: Balancing the risks and benefits

2015

Journal Article

Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial

Amin, Alpesh, Deitelzweig, Steve, Jing, Yonghua, Makenbaeva, Dinara, Wiederkehr, Daniel, Lin, Jay and Graham, John (2015). Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial. Clinical and Applied Thrombosis/Hemostasis, 21 (3), 235-240. doi: 10.1177/1076029613507335

Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial

2015

Conference Publication

Comparison of Major Bleeding Risk and Associated Costs Among Newly Anticoagulated Non-valvular Atrial Fibrillation Patients

Deitelzweig, Steven, Bruno, Amanda, Tate, Natalie, Ogbonnaya, Augustina, Shah, Manan, Farrelly, Eileen, Lokhandwala, Tasneem, Gupta, Kiran and Eaddy, Michael (2015). Comparison of Major Bleeding Risk and Associated Costs Among Newly Anticoagulated Non-valvular Atrial Fibrillation Patients. Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association (AHA), Orlando, United States, Nov 07-11, 2015. LIPPINCOTT WILLIAMS & WILKINS.

Comparison of Major Bleeding Risk and Associated Costs Among Newly Anticoagulated Non-valvular Atrial Fibrillation Patients

2015

Conference Publication

Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants

Deitelzweig, S., Bruno, A., Tate, N., Ogbonnaya, A., Shah, M., Farrelly, E., Lokhandwala, T., Gupta, K. and Eaddy, M. (2015). Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants. Congress of the European-Society-of-Cardiology (ESC), London, England, United Kingdom, Aug 29-Sep 02, 2015. OXFORD: OXFORD UNIV PRESS.

Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants

2015

Conference Publication

Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US

Deitelzweig, S., Bruno, A., Trocio, J., Tate, N., Gupta, K., Lin, J. and Lingohr-Smith, M. (2015). Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US. Congress of the European-Society-of-Cardiology (ESC), London, England, United Kingdom, Aug 29-Sep 02, 2015. OXFORD: OXFORD UNIV PRESS.

Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US

2015

Conference Publication

A Conservative Aproach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in An Integrated Healthcare Delivery System Setting in the U.S

Deitelzweig, S., Evans, M., Hillson, E., Trocio, J., Bruno, A., Tan, W., Lingohr-Smith, M. and Lin, J. (2015). A Conservative Aproach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in An Integrated Healthcare Delivery System Setting in the U.S. ISPOR 20th Annual International Meeting, Philadelphia, PA United States, 16-20 May 2015. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2015.03.848

A Conservative Aproach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in An Integrated Healthcare Delivery System Setting in the U.S

2014

Conference Publication

Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement Surgery

Deitelzweig, Steven, Nutescu, Edith A., Meyer, James, Lin, Jay, Lingohr-Smith, Melissa and Amin, Alpesh N. (2014). Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement Surgery. 56th Annual Meeting of the American-Society-of-Hematology, San Francisco Ca, Dec 06-09, 2014. WASHINGTON: AMER SOC HEMATOLOGY.

Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement Surgery

Supervision

Availability

Professor Steve Deitelzweig is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Professor Steve Deitelzweig's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au